Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Opus Genetics, Inc.NASDAQ: IRD
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $450K fell 55.8% year over year, behind the +224.6% change in trailing-twelve-month accounts receivables. Sequentially, it fell 59.6% from the prior quarter.
Context
- Accounts receivables amounted to 18.4% of revenue in FY2025, down 12.9 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -55.8% toward the trailing-twelve-month pace of +224.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 2.61M USD
- Year-over-year change
- +175.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.61M | +175.8% |
| FY2024 | 2024-12-31 | (3.44M) | -236.6% |
| FY2023 | 2023-12-31 | 2.52M | +151.9% |
| FY2022 | 2022-12-31 | (4.85M) | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Receivables vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's LTM Mar 2026 accounts receivables of $2.04M is the 3rd largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +224.6% is the highest of 6, against a peer median of +37.9%.
- Accounts receivables amounts to 17.0% of revenue for IRD, versus a peer median of 6.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.57M | -6016.2% | — | 5.3% | |
| LTM Mar 2026 | $2.53M | +162.9% | — | 220.4% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $2.04M | +224.6% | — | 17.0% |
| LTM Mar 2026 | $1.12M | +128.6% | +72.7% | — | |
| LTM Mar 2026 | $1.1M | +37.9% | — | 7.3% | |
| LTM Mar 2026 | $608K | — | — | — | |
| LTM Mar 2026 | $331.65K | -73.3% | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding IRD) | $0 | +37.9% | +72.7% | 6.3% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (56.69M) | 17.89M | (9.99M) | (57.53M) | (49.59M) |
| Depreciation & Amortization | 4K | 4K | 6K | 10K | 53K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.91M | 1.81M | 3.51M | 3.36M | 3.4M |
| Change in Working Capital | 181K | (5.56M) | 4.08M | 3.09M | (2.15M) |
| Accounts Receivables | 0 | (4.85M) | 2.52M | (3.44M) | 2.61M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 381K | (515K) | 1.08M | 220K | 7K |
| Other Working Capital | (200K) | (190K) | 477K | 6.31M | (4.77M) |
| Other Non-Cash Items | 35.22M | 170K | 1.28M | 25.49M | 13.04M |
| Operating Cash Flow | (19.37M) | 14.31M | (1.11M) | (25.58M) | (35.25M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (100K) | 0 | 0 | 1.21M | 0 |
| Investing Cash Flow | (100K) | 0 | 0 | 1.21M | 0 |
| Debt Repayment | 538K | (538K) | 0 | 0 | 1M |
| Common Stock Issued | 28.49M | 4.43M | 9.23M | 4.5M | 49.18M |
| Common Stock Repurchased | 0 | 0 | 0 | (79K) | (152K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.42M) | (104K) | (248K) | (232K) | 0 |
| Financing Cash Flow | 27.61M | 3.79M | 8.98M | 4.19M | 50.02M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.14M | 18.1M | 7.87M | (20.18M) | 14.77M |
| Free Cash Flow | (19.37M) | 14.31M | (1.11M) | (25.58M) | (35.25M) |
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.